Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gary Craig

Spokane, WA Medical Doctor

NPI 1508936436 CMS profile 22523

105 W 8Th Ave, Ste 6080, Spokane, WA 99204

Open in the dashboard

General payments

$328,202

559 records reported · program years 2019–2025

Research payments

$1,232

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$70,290 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Gary Craig of Spokane, WA is reported in the CMS Open Payments database as having received $328,202 across 559 general payments and $1,232 in research payments paid to them. Separately, studies naming them as principal investigator received $70,290 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,841 7
2024 General $5,952 11
2023 General $4,209 7
2022 General $32,751 39
2021 General $24,210 31
2021 Research $1,232 1
2020 General $51,938 110
2019 General $203,302 354

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gary Craig
  • Washington median
  • Middle half of Washington
  • National median

In program year 2025, general payments to Gary Craig were reported at $5,841. Among 15,799 Washington profiles paid that year, the median was $133 and the middle half received between $42 and $442.

Show as a table
Year Gary Craig Washington median Middle half National median
2019 $203,302 $126 $38–$506 $163
2020 $51,938 $90 $30–$291 $114
2021 $24,210 $107 $29–$344 $132
2022 $32,751 $124 $38–$398 $149
2023 $4,209 $129 $40–$423 $160
2024 $5,952 $133 $44–$454 $164
2025 $5,841 $133 $42–$442 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $61,421 128 payments
  2. Lilly USA, LLC $58,015 99 payments
  3. Regeneron Healthcare Solutions, Inc. $34,033 41 payments
  4. Novartis Pharmaceuticals Corporation $29,061 48 payments
  5. UCB, Inc. $28,883 42 payments
  6. Celgene Corporation $27,986 34 payments
  7. E.R. Squibb & Sons, L.L.C. $25,233 31 payments
  8. Pfizer Inc. $24,763 32 payments
  9. Gilead Sciences, Inc. $12,230 17 payments
  10. Genentech USA, Inc. $9,793 42 payments
  11. Other $16,784 45 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $196,157 93 payments
  2. Consulting Fee $66,141 25 payments
  3. Travel and Lodging $44,235 110 payments
  4. Food and Beverage $12,029 323 payments
  5. Honoraria $9,630 6 payments
  6. Education $11 2 payments
Products named General payments · program years 2019–2025
  1. Otezla Inflammation $58,290 67 payments
  2. TALTZ $35,512 46 payments
  3. KEVZARA $34,076 42 payments
  4. COSENTYX $28,229 44 payments
  5. Otezla Dermatology $27,986 34 payments
  6. Cimzia $24,211 37 payments
  7. ORENCIA $21,933 28 payments
  8. XELJANZ $16,079 23 payments
  9. OLUMIANT $13,835 6 payments
  10. Rituxan $9,566 41 payments
  11. Other $21,439 164 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. F. Hoffmann-La Roche AG $1,232 1 payment

Records

560 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record